Low-molecular-weight heparins in the treatment of venous thromboembolism
AUTOR(ES)
Ageno , Walter
FONTE
BioMed Central
RESUMO
Venous thromboembolism is a common disease that is associated with considerable morbidity if left untreated. Recently, low-molecular-weight heparins (LMWHs) have been evaluated for use in acute treatment of deep venous thrombosis and pulmonary embolism. Randomized studies have shown that LMWHs are as effective as unfractionated heparin in the prevention of recurrent venous thromboembolism, and are as safe with respect to the occurrence of major bleeding. A pooled analysis did not show substantial differences among different LMWH compounds used, but no direct comparison of the different LMWHs is currently available. Finally, in patients with pulmonary embolism, there is a relative lack of large studies of daily practice. It could be argued that large prospective studies, in patients who were treated with LMWHs from the moment of diagnosis, are needed.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=59610Documentos Relacionados
- Low-Molecular-Weight Heparins in the Cardiac Catheterization Laboratory
- New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins
- Pharmacological and clinical evidence for the use of low-molecular-weight heparins in acute coronary syndromes
- LOW-MOLECULAR-WEIGHT RHEUMATOID FACTOR*
- Rat and human HARE/stabilin-2 are clearance receptors for high- and low-molecular-weight heparins
